Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Affymetrix, Inc.    AFFX

SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

Affymetrix, Inc. : Wall Street Fundamentals Releases New In-Depth Stock Reports on AFFX, CATM, RGR and TRLA

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/02/2013 | 02:35pm CEST

Global markets rallied on positive economic data from the U.S. and China, sending the S&P 500 Index above the 1700 mark for the first time Thursday. Both the S&P 500 Index and the Down Jones have posted gains of approximately 19 percent year-to-date, while the Nasdaq and Russell 2000 have posted gains of roughly 21 percent and 25 percent, respectively. On Thursday, reports showed jobless claims in the U.S. declined 19,000 to $326,000, the lowest since January 2008. Additionally, the official China Manufacturing Purchasing Managers' for July increased to 50.3 from 50.1 in the previous month, any reading above 50 signals growth from the previous month.

Affymetrix, Inc. (NASDAQ: AFFX) shares traded in the range of $4.17 to $4.37 Thursday before settling to close at $4.32, an increase of 13.68 percent. The stock appears to be facing some resistance at the $44.28 and $4.47 level with some support at $4.12. The company reported second quarter revenues increased 20.0 percent year-over-year to $79.5 million. Shares of Affymetrix have gained approximately 36.0 percent year-to-date.

More information on Affymetrix and access to the free equity report can be found at:
www.WallStreetFundamentals.com/AFFX

Cardtronics, Inc. (NASDAQ: CATM) shares traded in the range of $29.80 to $33.26 Thursday before settling to close at $33.03, an increase of 12.10 percent. The stock appears to have some support at the $30.63 and $29.92 levels. The company reported second quarter adjusted Net Income per diluted share increased 29 percent year-over-year to $0.49. Shares of Cardtronics have gained approximately 39.0 percent year-to-date.

More information on Cardtronics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CATM

Sturm, Ruger & Company (NYSE: RGR) shares traded in the range of $52.62 to $55.40 Thursday before settling to close at $52.69, an increase of 3.58 percent. The stock appears to be facing some resistance at the $55.69 and $57.90 level with some support at $51.94. The company reported earnings in the second quarter grew 79 percent when compared to a year ago. Shares of Sturm, Ruger & Company have gained approximately 16.0 percent year-to-date.

More information on Sturm, Ruger & Company and access to the free equity report can be found at:
www.WallStreetFundamentals.com/RGR

Trulia Inc. (NYSE: TRLA) shares traded in the range of $42.24 to $47.97 Thursday before settling to close at $44.53, an increase of 19.51 percent. The stock appears to have some support at the $42.25 and $39.65 levels. The company reported second quarter revenues increased 77 percent year-over-year to $29.7 million. Shares of Trulia have gained approximately 174.0 percent year-to-date.

More information on Trulia and access to the free equity report can be found at:
www.WallStreetFundamentals.com/TRLA

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: [email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AFFYMETRIX, INC.
2016DJTHERMO FISHER SCIENTIFIC : Completes Acquisition of Affymetrix
2016DJTHERMO FISHER SCIENTIFIC : Completes Acquisition of Affymetrix
2016 AFFYMETRIX : Faruqi & Faruqi, LLP : Announces Filing of a Class Action Lawsuit A..
2016DJTHERMO FISHER SCIENTIFIC : Affymetrix Rejects a Rival Bid to Thermo Fisher's Mer..
2016DJTHERMO FISHER SCIENTIFIC : Affymetrix Rejects a Rival Bid to Thermo Fisher's Mer..
2016DJTHERMO FISHER SCIENTIFIC : Affymetrix Rejects a Rival Bid to Thermo Fisher's Mer..
2016DJTHERMO FISHER SCIENTIFIC : Affymetrix Rejects a Rival Bid to Thermo Fisher's Pla..
2016 AFFYMETRIX : to Engage in Discussions With Origin Technologies
2016DJAFFYMETRIX : Delays Merger Vote
2016DJTHERMO FISHER SCIENTIFIC : Affymetrix Delays Thermo Fisher Merger Vote After Hig..
More news
Sector news : Bio Diagnostics & Testing
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Diagnostics & Testing
News from SeekingAlpha
2016 WEEK IN REVIEW : Deals Dominate China Biopharma News
2016 IBM Buys Salesforce.com Cloud Consultant
2016 30% Annual Return From This Stock
2016 *Except For Amazon
2016 WALL STREET BREAKFAST : Yellen Speech Takes Center Stage
Advertisement
Chart AFFYMETRIX, INC.
Duration : Period :
Affymetrix, Inc. Technical Analysis Chart | AFFX | US00826T1088 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Managers
NameTitle
Seth H. Hoogasian Chief Executive Officer & Secretary
Robert H. Trice Independent Director
Gary S. Guthart Director
David A. Weber Chief Commercial Officer
Kim Caple Senior Vice President & GM-Clinical Business
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AFFYMETRIX, INC.0.00%0
MIRACA HOLDINGS INC.-2.28%2 640
BEIJING STRONG BIOTECH..--.--%1 244
SEEGENE INC--.--%823
GENSCRIPT BIOTECH CORP-6.49%760
INNATE PHARMA-21.90%666
More Results